Antibody with enhanced Fc alpha receptor binding affinity

Fc alpha receptor-binding antibody that activates neutrophils to maximize antibody effector mechanisms

This technology relates to an antibody that specifically binds to human Fc alpha receptors and its immunologically active fragments. It maximizes the mechanism of action of various antibody therapeutics by binding to Fc alpha receptors on effector cells while maintaining the IgG format.

Conventional IgA antibodies had limitations in utilizing effector functions, making it difficult to fully achieve the cell-killing effects (ADCC and ADCP) of antibody therapeutics.

This technology is designed to bind to Fc alpha receptors on neutrophils, which constitute the highest proportion of immune cells in mammals. It overcomes the limitations of conventional IgA by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP), and can be broadly applied as various Fc-fusion protein therapeutics.

‍

‍

Key Features:

• Antibody or immunologically active fragments (e.g., scFv, Fab) that specifically bind to human Fc alpha receptors
• Antibody composition comprising CDRH1, CDRH2, CDRH3, and VH domains
• Maintains IgG format and binds to Fc alpha receptors on effector cells such as neutrophils
• Maximization of antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP)